ClinicalTrials.gov
ClinicalTrials.gov Menu

Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02707861
Recruitment Status : Completed
First Posted : March 14, 2016
Last Update Posted : November 8, 2018
Sponsor:
Collaborator:
Westat
Information provided by (Responsible Party):
TaiMed Biologics Inc.

March 8, 2016
March 14, 2016
November 8, 2018
March 2016
November 2018   (Final data collection date for primary outcome measure)
  • Safety and Tolerability of ibalizumab + OBR assessed by the occurrence of Adverse Events and Discontinuations [ Time Frame: Through 48 weeks ]
    Safety and tolerability of ibalizumab combined with optimized background regimen, as assessed by the occurrence of Adverse Events and Discontinuations
  • Effectiveness of ibalizumab + OBR by Viral Load Log10 Change from Baseline (Cohort 2 only) [ Time Frame: At 7 days ]
    Proportion of patients in Cohort 2 achieving at least a 0.5 log10 decrease from Baseline in viral load at Day 7 of the study
Same as current
Complete list of historical versions of study NCT02707861 on ClinicalTrials.gov Archive Site
  • HIV Resistance [ Time Frame: Through 48 weeks ]
    HIV-1 sensitivity/susceptibility changes associated with virologic failure after administration of ibalizumab, as assessed by genotypic and phenotypic analysis of samples collected upon the occurrence of virologic failure as compared with Baseline samples
  • Effectiveness of ibalizumab + OBR by Viral Suppression to <50 Copies (Cohort 2 only) [ Time Frame: Through 48 weeks ]
    Proportion of patients in Cohort 2 with HIV-1 RNA levels <50 copies/mL at protocol-specified time points
  • Effectiveness of ibalizumab + OBR by Viral Suppression to <400 Copies (Cohort 2 only) [ Time Frame: Through 48 weeks ]
    Proportion of patients in Cohort 2 with HIV-1 RNA levels <400 copies/mL at protocol-specified time points
  • Effectiveness of ibalizumab + OBR by Mean Change in Viral Load from Baseline (Cohort 2 only) [ Time Frame: Through 48 weeks ]
    The mean change in viral load from Baseline measurement at study Day 7, and all other assessment time points for patients in Cohort 2
  • Effectiveness of ibalizumab + OBR by 0.5 Log10 Decrease in Viral Load from Baseline (Cohort 2 only) [ Time Frame: Through 48 weeks ]
    The proportion of patients in Cohort 2 achieving at least a 0.5 log10 decrease in viral load from Baseline measurement at all assessment time points
  • Effectiveness of ibalizumab + OBR by 1.0 Log10 Decrease in Viral Load from Baseline (Cohort 2 only) [ Time Frame: Through 48 weeks ]
    The proportion of patients in Cohort 2 achieving at least a 1.0 log10 decrease in viral load from Baseline measurement at all assessment time points
Same as current
Not Provided
Not Provided
 
Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1
A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1
Ibalizumab is a monoclonal antibody that works by blocking HIV entry into the immune system cells (CD4+ or T-cells) the virus typically infects. Ibalizumab is intended for use in combination with other anti-HIV drugs in people with multi-drug resistant HIV and limited treatment options. This study will collect further information on the safety and tolerability of intravenously administered (IV) ibalizumab combined with an optimized background regimen for treating multi-drug resistant HIV-1 infection, and will provide continuing access to ibalizumab for patients completing a prior ibalizumab clinical trial.

Participants will enroll into one of two study cohorts. Cohort 1 will provide continued administration of IV ibalizumab for patients completing a prior ibalizumab clinical trial (TaiMed-sponsored or Investigator-Sponsored). Patients will continue to receive IV infusions of ibalizumab at the dosage assigned in the previous study - either 800 mg once every two weeks, or 2000 mg once every four weeks.

Cohort 2 will provide IV ibalizumab, 800 mg once every two weeks, for qualifying patients with multi-drug resistant HIV-1 and limited treatment options who have never previously received ibalizumab.

Participants may continue in this study for 48 weeks, or until ibalizumab becomes commercially available, whichever occurs first.

Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
HIV
  • Drug: ibalizumab
    Intravenous infusion of humanized monoclonal antibody binding with a region of Domain 2 of CD4 receptor, blocking post-attachment conformational changes necessary for HIV cell entry
    Other Name: TNX-355, Hu5A8
  • Drug: Optimized Background Regimen
    An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing. The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).
  • Experimental: Cohort 1

    IV ibalizumab (combined with optimized background regimen):

    800 mg once every two weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial

    OR

    2000 mg once every four weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial

    Administered for 48 weeks, or until ibalizumab becomes commercially available

    Interventions:
    • Drug: ibalizumab
    • Drug: Optimized Background Regimen
  • Experimental: Cohort 2

    IV ibalizumab (combined with optimized background regimen):

    800 mg once every two weeks for qualifying patients who have never received ibalizumab

    Administered for 48 weeks, or until ibalizumab becomes commercially available

    Interventions:
    • Drug: ibalizumab
    • Drug: Optimized Background Regimen
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
79
50
November 2018
November 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

(Cohort 1)

  • Currently receiving ibalizumab via other TaiMed-sponsored or investigator-Sponsored protocol
  • Are capable of understanding and have voluntarily signed the informed consent document

(Cohort 2)

  • 18 years of age or older
  • Are capable of understanding and have voluntarily signed the informed consent document
  • Have documented HIV-1 infection by official, signed, written history (e.g., laboratory report), otherwise an HIV-antibody test will be performed
  • Are able and willing to comply with all protocol requirements and procedures
  • Have a viral load >1,000 copies/mL and documented resistance to at least one antiretroviral medication from each of three classes of antiretroviral medications as measured by previous viral resistance testing (resistance testing is not provided by the study for qualification purposes)
  • Have a history of at least 6 months on antiretroviral treatment
  • Are receiving a failing antiretroviral regimen OR have failed and are off therapy
  • Have viral sensitivity/susceptibility to at least one antiretroviral agent, other than ibalizumab, as determined by previous resistance test performed within 6 months of screening and be willing and able to be treated with at least one agent to which the patient's viral isolate is fully sensitive/susceptible according to the resistance tests used for screening as a component of OBR
  • If sexually active, are willing to use an effective method of contraception during the study and for 30 days after the last administration of the study drug

Exclusion Criteria:

(Cohort 1)

  • There are no Exclusion Criteria for patients meeting the Inclusion Criteria for Cohort 1

(Cohort 2)

  • Eligible for participation in other TaiMed-sponsored clinical trials of ibalizumab
  • Any significant diseases (other than HIV-1 infection) or clinically significant findings, including psychiatric and behavioral problems, determined from screening, medical history and/or physical examination that, in the investigator's opinion, would preclude the patient from participating in this study
  • Any significant acute illness within 1 week before the first administration of investigational medication on this study
  • Any active infection secondary to HIV requiring acute therapy; however, patients that require maintenance therapy (i.e., secondary prophylaxis for opportunistic infections) will be eligible for the study.
  • Any immunomodulating therapy (including interferon), systemic steroids, or systemic chemotherapy within 4 weeks before Day 0
  • Any prior exposure to ibalizumab (formerly TNX-355 and Hu5A8)
  • Any vaccination within 7 days before Day 0
  • Any female patient who either is pregnant, intends to become pregnant, or is currently breastfeeding
  • Any current alcohol or illicit drug use that, in the investigator's opinion, will interfere with the patient's ability to comply with the study schedule and protocol evaluations
  • Any previous clinically significant allergy or hypersensitivity to any excipient in the ibalizumab formulation
  • Any radiation therapy during the 28 days before first administration of investigational medication on this study
  • Any clinically significant Grade 3 or 4 laboratory abnormality according to the Division of AIDS (DAIDS) grading scale, except for the following asymptomatic Grade 3 events:

    • triglyceride elevation
    • total cholesterol elevation
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Puerto Rico,   United States
 
 
NCT02707861
TMB-311
No
Not Provided
Plan to Share IPD: No
TaiMed Biologics Inc.
TaiMed Biologics Inc.
Westat
Principal Investigator: Stanley T. Lewis, MD, MPH TaiMed Biologics Inc.
TaiMed Biologics Inc.
November 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP